3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Active not recruiting
2
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
3
Recurrence
2
Neoplasms
2
Melanoma
2
Glioblastoma
2
Vulvar Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Skin Neoplasms
1
Rectal Neoplasms
1
Penile Neoplasms
1
Mesothelioma, Malignant
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Ependymoma
1
Disease Progression
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Advanced Squamous Non-Small Cell Lung Cancer
1
Adenocarcinoma
1
Interventions
Oxaliplatin
6
tislelizumab
3
Irinotecan
3
Fluorouracil
3
Chemotherapy, Adjuvant
3
Capecitabine
3
sintilimab
2
raltitrexed
2
pembrolizumab
2
Surgical Procedures, Operative
2
Specimen Handling
2
Neoadjuvant Therapy
2
HMPL-013
2
spartalizumab
1
rimegepant sulfate
1
encorafenib
1
cemiplimab
1
balstilimab
1
XELOX
1
Surgical Fixation Devices
1
Radiofrequency Ablation
1
Propranolol
1
Preoperative Exercise
1
Pemetrexed
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Mortality
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Laparoscopy
1
Immune Checkpoint Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Colonic Neoplasms
×
cemiplimab
×
Clear all
NCT07224022
2026-05-06
NACho
Duke University
Phase 2
Not yet recruiting
24 enrolled